| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-08-1978 |
| P698 | PubMed publication ID | 19318484 |
| P50 | author | Pasi A Jänne | Q74766165 |
| P2093 | author name string | Christine Powell | |
| Matthew J Ellis | |||
| Geoffrey I Shapiro | |||
| Howard A Burris | |||
| Tarek Mekhail | |||
| Michael J Naughton | |||
| Paula M Fracasso | |||
| Joseph P Eder | |||
| Suzanne F Jones | |||
| Ronald M Bukowski | |||
| Thomas J Lynch | |||
| Pamela N Munster | |||
| Richat Abbas | |||
| Susan Quinn | |||
| Charles Zacharchuk | |||
| Jennifer Vermette | |||
| Kwok-K Wong | |||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neratinib | Q6995920 |
| P304 | page(s) | 2552-2558 | |
| P577 | publication date | 2009-03-24 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors | |
| P478 | volume | 15 |
| Q47328841 | A biomaterial screening approach reveals microenvironmental mechanisms of drug resistance |
| Q37049733 | A gene expression profile indicative of early stage HER2 targeted therapy response |
| Q39374283 | A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers. |
| Q39559549 | A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatments. |
| Q39467165 | A novel treatment strategy for EGFR mutant NSCLC with T790M-mediated acquired resistance |
| Q33556988 | A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors |
| Q36785721 | Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment |
| Q35989963 | Advances in first-line treatment for patients with HER-2+ metastatic breast cancer |
| Q33810574 | Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor |
| Q46005851 | An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. |
| Q51727547 | An eco-friendly direct spectrofluorimetric method for the determination of irreversible tyrosine kinase inhibitors, neratinib and pelitinib: application to stability studies. |
| Q38077494 | An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents |
| Q33820374 | Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models |
| Q55309854 | Application of the CRISPR/Cas9 System to Drug Resistance in Breast Cancer. |
| Q37947902 | Beyond trastuzumab: new treatment options for HER2-positive breast cancer |
| Q35653820 | Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer |
| Q37788248 | Biological considerations and clinical applications of new HER2-targeted agents |
| Q36896150 | Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer |
| Q36085503 | Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR-T790M mutant lung cancer |
| Q90074730 | Conformational Insight on WT- and Mutated-EGFR Receptor Activation and Inhibition by Epigallocatechin-3-Gallate: Over a Rational Basis for the Design of Selective Non-Small-Cell Lung Anticancer Agents |
| Q27851628 | Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling |
| Q33963199 | EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications |
| Q38106905 | EGFR tyrosine kinase inhibitors: difference in efficacy and resistance |
| Q39167876 | Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer |
| Q36250585 | Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence |
| Q38708134 | Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo |
| Q38211951 | Emerging EGFR antagonists for breast cancer. |
| Q37970020 | ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective |
| Q28972291 | Evolving Therapies and FAK Inhibitors for the Treatment of Cancer |
| Q37643985 | Evolving novel anti-HER2 strategies |
| Q38585702 | Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress |
| Q90655751 | HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer |
| Q38153447 | HER2 and lung cancer |
| Q34974436 | HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies |
| Q37826199 | Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity? |
| Q35599781 | Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer. |
| Q38728508 | Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer |
| Q26866186 | Irreversible EGFR-TKIs: dreaming perfection |
| Q49530239 | LC-MS/MS assay for the quantitation of the tyrosine kinase inhibitor neratinib in human plasma |
| Q30502341 | MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents |
| Q38669280 | Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update |
| Q35043706 | Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer |
| Q37751530 | Molecular basis for therapy resistance |
| Q38024121 | Neratinib (HKI-272) in the treatment of breast cancer. |
| Q38692311 | Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer. |
| Q27853337 | Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial |
| Q38666768 | Neratinib for the treatment of HER2-positive early stage breast cancer. |
| Q39333848 | Neratinib for the treatment of breast cancer |
| Q28071303 | Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness |
| Q38718320 | Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4. |
| Q36057369 | Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo. |
| Q36103790 | Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo. |
| Q38965974 | Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo |
| Q46039755 | Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2+ breast cancer. |
| Q97419545 | Neratinib-Induced Duodenal Ulcer: A Case Report |
| Q50201250 | Neratinib: First Global Approval |
| Q37603346 | Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer |
| Q37016382 | New developments in the treatment of HER2-positive breast cancer |
| Q39200319 | New protein kinase inhibitors in breast cancer: afatinib and neratinib |
| Q35807946 | Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib |
| Q28079320 | Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence |
| Q98154617 | Novel HER2-targeted therapies for HER2-positive metastatic breast cancer |
| Q64094063 | Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial |
| Q36089579 | Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer |
| Q37776547 | Personalized therapies in the cancer "omics" era |
| Q38861026 | Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations |
| Q39390081 | Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects |
| Q34829983 | Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects |
| Q34625315 | Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors |
| Q33396953 | Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors |
| Q92376425 | Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer |
| Q34274925 | Present and future evolution of advanced breast cancer therapy |
| Q27012540 | Profile of neratinib and its potential in the treatment of breast cancer |
| Q35040295 | Promising molecular targeted therapies in breast cancer |
| Q52592302 | Raman Micro-Spectroscopic Evidence for the Metabolism of a Tyrosine Kinase Inhibitor, Neratinib, in Cancer Cells. |
| Q57466084 | Raman micro-spectroscopy monitors acquired resistance to targeted cancer therapy at the cellular level |
| Q39661497 | Rapid detection of the epidermal growth factor receptor mutation in non-small-cell lung cancer for analysis of acquired resistance using molecular beacons |
| Q34773458 | Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer |
| Q28083239 | Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance |
| Q38023942 | Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer. |
| Q37802782 | Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment |
| Q48308202 | Risk of gastrointestinal complications in breast cancer patients treated with neratinib: a meta-analysis. |
| Q34417886 | Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer |
| Q58108246 | Safety and Efficacy Profile of Neratinib: A Systematic Review and Meta-Analysis of 23 Prospective Clinical Trials |
| Q92814902 | Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10 |
| Q54484711 | Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. |
| Q43599415 | Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Research Program phase I study |
| Q34433903 | Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer |
| Q36904574 | Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers |
| Q35116206 | Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors |
| Q38838227 | Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR. |
| Q92298870 | TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases |
| Q33555473 | Tailored targeted therapy for all: a realistic and worthwhile objective? |
| Q38625550 | Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives |
| Q37728765 | Targeted therapy in breast cancer: current status and future directions |
| Q37781113 | Targeted therapy: an evolving world of lung cancer. |
| Q46087491 | Targeting protein quality control pathways in breast cancer |
| Q35583942 | Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review |
| Q37990044 | Targeting the epidermal growth factor receptor in solid tumor malignancies. |
| Q34096063 | The Role of Targeted Agents in the Treatment of Metastatic Breast Cancer. |
| Q89746470 | The paradox of cancer genes in non-malignant conditions: implications for precision medicine |
| Q37715991 | The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors |
| Q27021738 | The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer |
| Q38664492 | The role of neratinib in HER2-driven breast cancer. |
| Q34268618 | Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer |
| Q98464497 | Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib |
| Q37350784 | Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases |
| Q54573289 | Trastuzumab and lapatinib modulation of HER2 tyrosine/threonine phosphorylation and cell signaling. |
| Q38052616 | Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients |
| Q34326536 | Treating breast cancer in the 21st century: emerging biological therapies |
| Q34494115 | Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer |
| Q37772792 | Treatment strategy for HER2-positive breast cancer |
Search more.